Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma

International Journal of Colorectal Disease

Volumn 27, Issue 11, 2012, Pages 1391-1399

  Knösel, Thomas ^a   Chen, Yuan ^b   Hotovy, Stefanie ^b   Settmacher, Utz ^b   Altendorf Hofmann, Annelore ^b   Petersen, Iver ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

CDX2; Colorectal adenocarcinoma; Desmocollin 1 3 (DSC1 3); Immunohistochemistry; PITX1; Prognostic markers

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIOLOGICAL MARKER; COMPLEMENT FACTOR H; CYCLIN DEPENDENT KINASE 4; DESMOCOLLIN; DESMOCOLLIN 1; DESMOCOLLIN 2; DESMOCOLLIN 3; MESSENGER RNA; PROTEIN MDM2; TLE1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PITX1; UNCLASSIFIED DRUG; UVOMORULIN;

AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CDX2 GENE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DESMOCOLLIN 1 GENE; DESMOCOLLIN 2 GENE; DESMOCOLLIN 3 GENE; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; HOMEOBOX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PITUITARY HOMEOBOX 1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; AZACITIDINE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DESMOCOLLINS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PAIRED BOX TRANSCRIPTION FACTORS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84867989160     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1460-4     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
2. Galanis E, Alberts SR, O'Connell MJ (2000) New adjuvant therapy for colon cancer: Justified hope or commercial hype. Surg Oncol Clin N Am 9(4):813-823, discussion 825-816
3. Merkel S, Mansmann U, Papadopoulos T,Wittekind C, Hohenberger W, Hermanek P (2001) The prognostic inhomogeneity of colorectal carcinomas stage III: A proposal for subdivision of stage III. Cancer 92(11):2754-2759
4. Knösel T, Emde A, Schluns K, Chen Y, Jurchott K, Krause M, Dietel M, Petersen I (2005) Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 7(8):741-747
5. Knösel T, Emde V, Schluns K, Schlag PM, Dietel M, Petersen I (2006) Cytokeratin profiles identify diagnostic signatures in colorectal cancer using multiplex analysis of tissue microarrays. Cell Oncol 28(4):167-175
6. Simon R, Mirlacher M, Sauter G (2010) Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 664:113-126
7. Chen Y, Knosel T, Ye F, Pacyna-Gengelbach M, Deutschmann N, Petersen I (2007) Decreased PITX1 homeobox gene expression in human lung cancer. Lung Cancer 55(3):287-294
8. Chen YN, Chen H, Xu Y, Zhang X, Luo Y (2008) Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance.World J Gastroenterol 14(2):292-297
9. Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R (2005) A genetic screen identifies pitx1 as a suppressor of ras activity and tumorigenicity. Cell 121(6):849-858
10. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H, Eshima K (2011) Differential gene expression signatures between colorectal cancers with and without kras mutations: Crosstalk between the kras pathway and other signalling pathways. Eur J Cancer.
11. Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, Danenberg PV, DeMeester TR (2005) Increased cdx2 and decreased pitx1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 138(5):924-931
12. Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S (2009) Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 15 (14):4665-4673
13. Funakoshi S, Ezaki T, Kong J, Guo RJ, Lynch JP (2008) Repression of the desmocollin 2 gene expression in human colon cancer cells is relieved by the homeodomain transcription factors CDX1 and CDX2. Mol Cancer Res 6(9):1478-1490
14. Khan K, Hardy R,Haq A, Ogunbiyi O,Morton D, ChidgeyM(2006) Desmocollin switching in colorectal cancer. Br J Cancer 95 (10):1367-1370
15. Yin T, Green KJ (2004) Regulation of desmosome assembly and adhesion. Semin Cell Dev Biol 15(6):665-677
16. Heuser A, Plovie ER, Ellinor PT, Grossmann KS, Shin JT, Wichter T, Basson CT, Lerman BB, Sasse-Klaassen S, Thierfelder L, MacRae CA, Gerull B (2006) Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 79(6):1081-1088
17. Kottke MD, Delva E, Kowalczyk AP (2006) The desmosome: Cell science lessons from human diseases. J Cell Sci 119(Pt 5):797-806
18. Bell A, Bell D, Weber RS, El-Naggar AK (2011) Cpg island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer.
19. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS Inactivation of ras gtpase-activating proteins promotes unrestrained activity of wild-type ras in human liver cancer. J Hepatol 54 (2):311-319.
20. Cui T, Chen Y, Yang L, Knosel T, Zoller K, Huber O, Petersen I (2011) DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br J Cancer 104(6):1013-1019